v3.22.2.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net income (loss) $ (85,058) $ (83,387)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Share-based compensation expense 1,320 2,515
Amortization of debt discount and debt issuance costs 12,356 12,672
Depreciation and amortization expense 24,770 25,482
Change in acquired contingent consideration obligation (10,709) (4,224)
Non-cash royalty revenue (4,762) (8,889)
Deferred tax provision (benefit) 28,300 (6,788)
Change in derivative liability (37) (868)
Changes in assets and liabilities:    
Decrease in accounts receivable 2,312 6,606
(Increase) decrease in prepaid expenses and other current assets (258) 2,629
Decrease in inventory 3,297 5,813
Increase in other assets (237)  
(Decrease) increase in accounts payable, accrued expenses and other current liabilities (844) 4,875
Decrease in other non-current liabilities (439) (1,024)
Net cash used in operating activities (29,990) (44,588)
Cash flows from investing activities:    
Proceeds from sale of Chelsea facility, net   73,969
Purchases of property and equipment (136) (164)
Purchases of intangible assets (123) (26)
Net cash (used in) provided by investing activities (259) 73,779
Cash flows from financing activities:    
Repayment of Convertible Senior Notes Due 2021   (69,000)
Repayment of loans payable   (655)
Net cash used in financing activities   (69,655)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (790) (511)
Net decrease in cash, cash equivalents and restricted cash (31,040) (40,975)
Cash, cash equivalents and restricted cash at beginning of period 65,223 102,895
Cash, cash equivalents and restricted cash at end of period 34,183 61,920
Supplemental disclosure:    
Cash paid for interest 947 6
Cash paid for taxes $ 133 $ 46